The U.S. Food and Drug Administration has granted qualified infectious disease product (QIDP) designation to two Bayer investigational agents, Amikacin Inhale and Ciprofloxacin Dry Powder for Inhalation (DPI).

View article:
Bayer’s Amikacin Inhale and Ciprofloxacin DPI receive QIDP designation from FDA